|
Essential Hypertension
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Thus, we assessed the relationship between RGS5 genetic polymorphisms and essential hypertension (EH) in Chinese.
|
19863299 |
2009 |
|
Essential Hypertension
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Association of regulator of G protein signaling (RGS5) gene variants and essential hypertension in Mongolian and Han populations.
|
26782409 |
2015 |
|
Essential Hypertension
|
0.320 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
PSYGENET |
RGS2 and RGS5 genotypes predicted severity of baseline symptoms in schizophrenia.
|
18262772 |
2008 |
|
Schizophrenia
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
RGS2 and RGS5 genotypes predicted severity of baseline symptoms in schizophrenia.
|
18262772 |
2008 |
|
Schizophrenia
|
0.310 |
GeneticVariation
|
disease |
LHGDN |
RGS2 and RGS5 genotypes predicted severity of baseline symptoms in schizophrenia.
|
18262772 |
2008 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The most immunogenic TAAs for HCC are survivin, CCND1, and RGS5.
|
28330473 |
2017 |
|
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that over-expression of RGS5 promotes tumor metastasis by inducing epithelial-mesenchymal transition in HCC.
|
23868206 |
2013 |
|
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Studies conducted to localize the protein products of these genes by immunohistochemical staining of tissue arrays with up to 350 cores of tissues, and by in situ hybridization led to the discovery of novel sinusoidal endothelial cell markers in hepatocellular carcinoma: podocalyxin-like and regulator of G protein signaling-5.
|
15154008 |
2004 |
|
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Nuclear grade, RGS5 expression, and EpCAM expression were significantly higher in the PD-L1-positive HCC group compared with the PD-L1-negative HCC group (P<0.05).
|
31423211 |
2019 |
|
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining for RGS5 in 60 HCC cases demonstrated that RGS5 protein levels were higher in cancerous tissue compared with paired noncancerous tissue in 63.3% of HCC cases.
|
29434872 |
2018 |
|
Atherosclerosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our study identifies a common variant rs1056515 as a genetic marker for CAD and rare variants in LD with rs1056515 leading to decreased expression of RGS5, which contributes to atherosclerosis by impairing endothelial cell function.
|
31605122 |
2019 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
LHGDN |
Expression profiling identifies smooth muscle cell diversity within human intima and plaque fibrous cap: loss of RGS5 distinguishes the cap.
|
16293795 |
2006 |
|
Renal Cell Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Northern analysis further confirmed the up-regulation in expression of RGS-5 and Notch-3 in RCC.
|
11072240 |
2000 |
|
Renal Cell Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining using serial sections for endothelial cell markers (CD31 and CD34) and smooth muscle cell markers (alpha-SMA and desmin), as well as fluorescence double staining, strongly suggested that tumour endothelial cells were the main location of RGS5 in RCC.
|
15095478 |
2004 |
|
Neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Genes of regulator of G-protein signaling 5 in neuroblastoma cells and CHC1-L in lymphocytes increased after exposure to hydrostatic pressure.
|
14504426 |
2003 |
|
Neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Specifically, the expression patterns of GAPDH, TOMM5, SLC25A4, COII, QARS, and RGS5 genes were determined in SHSY5Y human neuroblastoma cells exposed to OA for 3, 24, or 48 h. All these genes showed alterations in their expression levels after at least one of the OA treatments tested.
|
22788371 |
2012 |
|
Ovarian Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
RGS5 was highly expressed in the cytoplasm of ovarian carcinoma cells and in microvascular structures.
|
30365142 |
2019 |
|
Ovarian Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Supporting these findings, we show elevated levels of Rgs5 mRNA in the stroma from strongly (as opposed to weakly) angiogenic ovarian carcinoma xenografts and accordingly, we also show more of the protein associated to the abnormal vasculature.
|
22130514 |
2012 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Northern analysis further confirmed the up-regulation in expression of RGS-5 and Notch-3 in RCC.
|
11072240 |
2000 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining using serial sections for endothelial cell markers (CD31 and CD34) and smooth muscle cell markers (alpha-SMA and desmin), as well as fluorescence double staining, strongly suggested that tumour endothelial cells were the main location of RGS5 in RCC.
|
15095478 |
2004 |
|
Central neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Specifically, the expression patterns of GAPDH, TOMM5, SLC25A4, COII, QARS, and RGS5 genes were determined in SHSY5Y human neuroblastoma cells exposed to OA for 3, 24, or 48 h. All these genes showed alterations in their expression levels after at least one of the OA treatments tested.
|
22788371 |
2012 |
|
Central neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Genes of regulator of G-protein signaling 5 in neuroblastoma cells and CHC1-L in lymphocytes increased after exposure to hydrostatic pressure.
|
14504426 |
2003 |
|
Malignant neoplasm of ovary
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
RGS5 was highly expressed in the cytoplasm of ovarian carcinoma cells and in microvascular structures.
|
30365142 |
2019 |